Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Greten Website

Tim F. Greten, M.D.

Selected Publications

1)  Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF, Korangy F.
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Gastroenterology. 135: 234-43, 2008.
[Journal]
2)  Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F.
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.
Hepatology. 50: 799-807, 2009.
[Journal]
3)  Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F.
Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells.
Blood. 117: 6532-41, 2011.
[Journal]
4)  Gamrekelashvili J, Kapanadze T, Han M, Wissing J, Ma C, Jaensch L, Manns MP, Armstrong T, Jaffee E, White AO, Citrin DE, Korangy F, Greten TF.
Peptidases released by necrotic cells control CD8+ T cell cross-priming.
J. Clin. Invest. 123: 4755-68, 2013.
[Journal]
5)  Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, Zender L, Kapoor V, Felsher DW, Manns MP, Korangy F, Greten TF.
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
J. Hepatol. 59: 1007-13, 2013.
[Journal]
6)  Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardière C, Boucher E, Fartoux L, Faivre S, Blanc J, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, André T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon J, Wendum D, Rosmorduc O, Greten TF.
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Lancet Oncol. [Epub ahead of print], 2014.
[Journal]
7)  Medina-Echeverz J, Haile LA, Zhao F, Gamrekelashvili J, Ma C, Métais J, Dunbar CE, Kapoor V, Manns MP, Korangy F, Greten TF.
IFN-gamma regulates survival and function of tumor-induced CD11b(+) Gr-1(high) myeloid derived suppressor cells by modulating the anti-apoptotic molecule Bcl2a1.
Eur. J. Immunol. [Epub ahead of print], 2014.
[Journal]
8)  Hato T, Goyal L, Greten TF, Duda DG, Zhu AX.
Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions.
Hepatology. [Epub ahead of print], 2014.
[Journal]
9)  Duffy AG, Greten TF.
Immunological off-target effects of standard treatments in gastrointestinal cancers.
Ann. Oncol. 25: 24-32, 2014.
[Journal]
10)  Greten TF.
Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity?.
Gut. [Epub ahead of print], 2014.
[Journal]
11)  Malek NP, Schmidt S, Huber P, Manns MP, Greten TF.
The diagnosis and treatment of hepatocellular carcinoma.
Dtsch Arztebl Int. 111: 101-6, 2014.
[Journal]
12)  Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ.
[Diagnosis of and therapy for hepatocellular carcinoma].
Z Gastroenterol. 51: 1269-326, 2013.
[Journal]
13)  Duffy A, Zhao F, Haile L, Gamrekelashvili J, Fioravanti S, Ma C, Kapanadze T, Compton K, Figg WD, Greten TF.
Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies.
Cancer Immunol. Immunother. 62: 299-307, 2013.
[Journal]
14)  Boeck S, Jung A, Laubender RP, Neumann J, Egg R, Goritschan C, Vehling-Kaiser U, Winkelmann C, Fischer von Weikersthal L, Clemens MR, Gauler TC, Märten A, Klein S, Kojouharoff G, Barner M, Geissler M, Greten TF, Mansmann U, Kirchner T, Heinemann V.
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Br. J. Cancer. 108: 469-76, 2013.
[Journal]
15)  Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF.
Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10.
Gut. 62: 1667-8, 2013.
[Journal]
16)  Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF.
Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database.
United European Gastroenterol J. 1: 351-7, 2013.
[Journal]
17)  Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S.
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Gut. 62: 751-9, 2013.
[Journal]
18)  Duffy A, Wilkerson J, Greten TF.
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.
Hepatology. 57: 1068-77, 2013.
[Journal]
19)  Greten TF, Duffy AG, Korangy F.
Hepatocellular carcinoma from an immunological perspective.
Clin. Cancer Res. 19: 6678-85, 2013.
[Journal]
20)  Abi-Jaoudeh N, Duffy AG, Greten TF, Kohn EC, Clark TW, Wood BJ.
Personalized oncology in interventional radiology.
J Vasc Interv Radiol. 24: 1083-92, 2013.
[Journal]
21)  Duffy A, Rahma O, Greten TF.
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
Int. J. Cancer. 132: 1718, 2013.
[Journal]
22)  Eggert T, McGlynn K, Greten TF, Altekruse S.
Response to fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: better 5-year survival or artefactual result of research methodology?.
Gut. [Epub ahead of print], 2013.
[Journal]
23)  Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF.
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Ann. Oncol. 24: 1972-9, 2013.
[Journal]
24)  Ma C, Kapanadze T, Gamrekelashvili J, Manns MP, Korangy F, Greten TF.
Anti-Gr-1 antibody depletion fails to eliminate hepatic myeloid-derived suppressor cells in tumor-bearing mice.
J. Leukoc. Biol. 92: 1199-206, 2012.
[Journal]
25)  Zhao F, Korangy F, Greten TF.
Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma.
Dig Dis. 30: 477-82, 2012.
[Journal]
26)  Knueppel M, Kubicka S, Vogel A, Malek NP, Schneider M, Papendorf F, Greten T, Wedemeyer J, Schneider A.
Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis.
Gastroenterol Res Pract. 2012: 190708, 2012.
[Journal]
27)  Zhao F, Hoechst B, Gamrekelashvili J, Ormandy LA, Voigtländer T, Wedemeyer H, Ylaya K, Wang XW, Hewitt SM, Manns MP, Korangy F, Greten TF.
Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses.
J Immunol. 88: 6055-62, 2012.
[Journal]
28)  Greten TF, Zhao F, Gamrekelashvili J, Korangy F.
Human Th17 cells in patients with cancer: Friends or foe?.
Oncoimmunology. 1: 1438-1439, 2012.
[Journal]
29)  Haile LA, Greten TF, Korangy F.
Immune suppression: the hallmark of myeloid derived suppressor cells.
Immunol. Invest. 41: 581-94, 2012.
[Journal]
30)  Rahma OE, Greten TF, Duffy A.
Locally advanced cancer of the esophagus, current treatment strategies, and future directions.
Front Oncol. 2: 52, 2012.
[Journal]
31)  Gamrekelashvili J, Ormandy LA, Heimesaat MM, Kirschning CJ, Manns MP, Korangy F, Greten TF.
Primary sterile necrotic cells fail to cross-prime CD8(+) T cells.
Oncoimmunology. 1: 1017-1026, 2012.
[Journal]
32)  Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, Scherubl H, Scheulen ME, Germanidis G, Dominguez S, Ricci S, Nadel A, Moscovici M, Voliotis D, Llovet JM.
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
J. Hepatol. 56: 1080-8, 2012.
[Journal]
33)  Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, Greten TF, Korangy F.
S100A9 a new marker for monocytic human myeloid-derived suppressor cells.
Immunology. 136: 176-83, 2012.
[Journal]
34)  Greten TF.
[Improved survival in patients with NET of the pancreas with molecular therapies].
Z Gastroenterol. 49: 1489-90, 2011.
[Journal]
35)  Schmidt S, Follmann M, Malek N, Manns MP, Greten TF.
Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma.
J. Gastroenterol. Hepatol. 26: 1779-86, 2011.
[Journal]
36)  von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismüller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP.
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.
Scand J Gastroenterol. 46: 1092-8, 2011.
[Journal]
37)  Greten TF, Manns MP, Korangy F.
Myeloid derived suppressor cells in human diseases.
Int Immunopharmacol. 11: 802-7, 2011.
[Journal]
38)  Greten TF.
[First standard chemotherapy for cholangiocellular carcinoma].
Z Gastroenterol. 48: 850-1, 2010.
[Journal]
39)  Greten TF, Forner A, Korangy F, N'Kontchou G, Barget N, Ayuso C, Ormandy LA, Manns MP, Beaugrand M, Bruix J.
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.
BMC Cancer. 10: 209, 2010.
[Journal]
40)  Haile LA, Gamrekelashvili J, Manns MP, Korangy F, Greten TF.
CD49d Is a New Marker for Distinct Myeloid-Derived Suppressor Cell Subpopulations in Mice.
J Immunol. 185: 203-10, 2010.
[Journal]
41)  Pischke S, Tutarel O, Greten TF, Heim A, Wedemeyer J, Herzog P, Saddekni N, Barg-Hock H, Strassburg C, Manns MP, Rifai K, Gebel M.
CMV-Enterocolitis as a Cause for Repeated Intestinal Intussusceptions in an Adult Patient after Liver Transplantation?.
Z Gastroenterol. 48: 688-92, 2010.
[Journal]
42)  Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L.
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Eur J Gastroenterol Hepatol. 22: 391-8, 2010.
[Journal]
43)  Boeck S, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler T, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Neugebauer S, Heinemann V.
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Anticancer Drugs. 21: 94-100, 2010.
[Journal]
44)  Stange MA, Tutarel O, Pischke S, Schneider A, Strassburg CP, Becker T, Barg-Hock H, Bastürk M, Wursthorn K, Cornberg M, Ott M, Greten TF, Manns MP, Wedemeyer H.
Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab.
Z Gastroenterol. 48: 258-63, 2010.
[Journal]
45)  Korangy F, Höchst B, Manns MP, Greten TF.
Immune responses in hepatocellular carcinoma.
Dig Dis. 28: 150-4, 2010.
[Journal]
46)  Korangy F, Höchst B, Manns MP, Greten TF.
Immunotherapy of hepatocellular carcinoma.
Expert Rev Gastroenterol Hepatol. 4: 345-53, 2010.
[Journal]
47)  Vosskuhl K, Greten TF, Manns MP, Korangy F, Wedemeyer J.
Lipopolysaccharide-Mediated Mast Cell Activation Induces IFN-{gamma} Secretion by NK Cells.
J Immunol. 185: 119-25, 2010.
[Journal]
48)  Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, Manns MP, Korangy F.
Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.
J. Immunother. 33: 211-8, 2010.
[Journal]
49)  Plentz RR, Manns MP, Greten TF.
Molecular therapy of pancreatic cancer.
Minerva Endocrinol. 35: 27-33, 2010.
[Journal]
50)  Tutarel O, Barg-Hock H, Pischke S, Bahr MJ, Kreipe HH, Greten TF, Manns MP, Strassburg CP.
Mycosis fungoides with involvement of the larynx after liver transplantation in an adult.
Am. J. Gastroenterol. 105: 238-40, 2010.
[Journal]
51)  Greten TF, Korangy F.
Radiofrequency ablation for the treatment of HCC - Maybe much more than simple tumor destruction?.
J Heptol. 53: 775-6, 2010.
[Journal]
52)  Greten TF, Manns MP, Malek N.
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Z Gastroenterol. 47: 55-60, 2009.
[Journal]
53)  Zhao F, Vermeer B, Lehmann U, Kreipe H, Manns MP, Korangy F, Greten TF.
Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma.
Immunology. 128: 134-40, 2009.
[Journal]
54)  Zhao F, Obermann S, von Wasielewski R, Haile L, Manns MP, Korangy F, Greten TF.
Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma.
Immunology. 128: 141-9, 2009.
[Journal]
55)  Greten TF, Korangy F, Manns MP, Malek NP.
Molecular therapy for the treatment of hepatocellular carcinoma.
Br. J. Cancer. 100: 19-23, 2009.
[Journal]
56)  Greten TF, Manns MP.
[Hepatocellular carcinoma - diagnosis and treatment].
Dtsch. Med. Wochenschr. 133: 1907-10, 2008.
[Journal]
57)  Ciesek S, Kirchhoff T, Niehaus M, Manns MP, Greten TF.
[Suspicion of a newly appearing hypertrophic obstructive cardiomyopathy in a patient treated for hepatocellular carcinoma].
Dtsch. Med. Wochenschr. 133: 2209-12, 2008.
[Journal]
58)  Lankiewicz S, Zimmermann S, Hollmann C, Hillemann T, Greten TF.
Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer.
Mol Oncol. 2: 349-55, 2008.
[Journal]
59)  Gueler F, Rong S, Gwinner W, Mengel M, Bröcker V, Schön S, Greten TF, Hawlisch H, Polakowski T, Schnatbaum K, Menne J, Haller H, Shushakova N.
Complement 5a receptor inhibition improves renal allograft survival.
J. Am. Soc. Nephrol. 19: 2302-12, 2008.
[Journal]
60)  Greten TF, Manns MP, Korangy F.
Immunotherapy of HCC.
Rev Recent Clin Trials. 3: 31-9, 2008.
[Journal]
61)  Haile LA, von Wasielewski R, Gamrekelashvili J, Krüger C, Bachmann O, Westendorf AM, Buer J, Liblau R, Manns MP, Korangy F, Greten TF.
Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
Gastroenterology. 135: 871-81, 881.e1-5, 2008.
[Journal]
62)  Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J.
Sorafenib in advanced hepatocellular carcinoma.
N. Engl. J. Med. 359: 378-90, 2008.
[Journal]
63)  Lankiewicz S, Rother E, Zimmermann S, Hollmann C, Korangy F, Greten TF.
Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells.
Cell. Oncol. 30: 463-71, 2008.
[Journal]
64)  Krüger C, Greten TF, Korangy F.
Immune based therapies in cancer.
Histol. Histopathol. 22: 687-96, 2007.
[Journal]
65)  Gamrekelashvili J, Krüger C, von Wasielewski R, Hoffmann M, Huster KM, Busch DH, Manns MP, Korangy F, Greten TF.
Necrotic tumor cell death in vivo impairs tumor-specific immune responses.
J. Immunol. 178: 1573-80, 2007.
[Journal]
66)  Ruthotto F, Papendorf F, Wegener G, Unger G, Dlugosch B, Korangy F, Manns MP, Greten TF.
Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer.
Ann. Oncol. 18: 1518-22, 2007.
[Journal]
67)  Obermann S, Petrykowska S, Manns MP, Korangy F, Greten TF.
Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Immunology. 122: 90-7, 2007.
[Journal]
68)  Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H, Merkesdal S, Frericks B, Zender L, Malek NP, Greten TF, Kubicka S, Manns MP, Galanski M.
Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
HBPD INT. 6: 259-66, 2007.
[Journal]
69)  Zieglschmid V, Hollmann C, Mannel J, Albert W, Jaeschke-Melli S, Eckstein B, Hillemann T, Greten TF, Gross E, Böcher O.
Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer.
Anticancer Res. 27: 1823-32, 2007.
[Journal]
70)  Greten TF.
[Molecular therapy for HCC?].
Z Gastroenterol. 44: 205-6, 2006.
[Journal]
71)  Greten TF, Blum HE, Manns MP, Geissler M.
[Treatment of hepatocellular carcinoma].
Z Gastroenterol. 44: 43-9, 2006.
[Journal]
72)  Kirchhoff TD, Rudolph KL, Layer G, Chavan A, Greten TF, Rosenthal H, Kubicka S, Galanski M, Manns MP, Schild H, Gallkowski U.
Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial.
Eur J Surg Oncol. 32: 201-7, 2006.
[Journal]
73)  Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M, Lehner F, Manns MP, Korangy F, Greten TF.
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma.
World J. Gastroenterol. 12: 3275-82, 2006.
[Journal]
74)  Garbe AI, Vermeer B, Gamrekelashvili J, von Wasielewski R, Greten FR, Westendorf AM, Buer J, Schmid RM, Manns MP, Korangy F, Greten TF.
Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Cancer Res. 66: 508-16, 2006.
[Journal]
75)  Greten TF, Manns MP, Korangy F.
Immunotherapy of hepatocellular carcinoma.
J. Hepatol. 45: 868-78, 2006.
[Journal]
76)  Greten TF, Manns MP, Reinisch I, Kaatsch P.
Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation.
Gut. 54: 732, 2005.
[Journal]
77)  Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F.
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
Cancer Res. 65: 2457-64, 2005.
[Journal]
78)  Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP.
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients.
Br. J. Cancer. 92: 1862-8, 2005.
[Journal]
79)  Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M.
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.
Cell. 118: 285-96, 2004.
[Journal]
80)  Kretschmer K, Stopkowicz J, Scheffer S, Greten TF, Weiss S.
Maintenance of peritoneal B-1a lymphocytes in the absence of the spleen.
J. Immunol. 173: 197-204, 2004.
[Journal]
81)  Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP, Greten TF.
Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Clin. Cancer Res. 10: 4332-41, 2004.
[Journal]
82)  Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, Manns MP, Greten TF.
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo.
Int. J. Cancer. 103: 205-11, 2003.
[Journal]
83)  Greten TF, Ott M.
CD40 in hepatocellular carcinoma: relevant or not?.
Eur J Gastroenterol Hepatol. 15: 113-4, 2003.
[Journal]
84)  Greten TF, Schneck JP.
Development and use of multimeric major histocompatibility complex molecules.
Clin. Diagn. Lab. Immunol. 9: 216-20, 2002.
[Journal]
85)  Greten TF, Korangy F, Neumann G, Wedemeyer H, Schlote K, Heller A, Scheffer S, Pardoll DM, Garbe AI, Schneck JP, Manns MP.
Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes.
J. Immunol. Methods. 271: 125-35, 2002.
[Journal]
86)  Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM.
Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis.
Gastroenterology. 123: 2052-63, 2002.
[Journal]
87)  Greten TF, Jaffee EM.
Cancer vaccines.
Curr Protoc Hum Genet. Chapter 13: Unit 13.8, 2001.
[Journal]
88)  Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S.
Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load.
J. Infect. Dis. 183: 197-205, 2001.
[Journal]
89)  Schneck JP, Slansky JE, O'Herrin SM, Greten TF.
Monitoring antigen-specific T cells using MHC-Ig dimers.
Curr Protoc Immunol. Chapter 17: Unit 17.2, 2001.
[Journal]
90)  Carruth LM, Greten TF, Murray CE, Castro MG, Crone SN, Pavlat W, Schneck JP, Siliciano RF.
An algorithm for evaluating human cytotoxic T lymphocyte responses to candidate AIDS vaccines.
AIDS Res. Hum. Retroviruses. 15: 1021-34, 1999.
[Journal]
91)  Greten TF, Jaffee EM.
Cancer vaccines.
J. Clin. Oncol. 17: 1047-60, 1999.
[Journal]
92)  Bieganowska K, Höllsberg P, Buckle GJ, Lim DG, Greten TF, Schneck J, Altman JD, Jacobson S, Ledis SL, Hanchard B, Chin J, Morgan O, Roth PA, Hafler DA.
Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy.
J. Immunol. 162: 1765-71, 1999.
[Journal]
93)  Howard MC, Spack EG, Choudhury K, Greten TF, Schneck JP.
MHC-based diagnostics and therapeutics - clinical applications for disease-linked genes.
Immunol. Today. 20: 161-5, 1999.
[Journal]
94)  Jaffee EM, Abrams R, Cameron J, Donehower R, Duerr M, Gossett J, Greten TF, Grochow L, Hruban R, Kern S, Lillemoe KD, O'Reilly S, Pardoll D, Pitt HA, Sauter P, Weber C, Yeo C.
A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma.
Hum. Gene Ther. 9: 1951-71, 1998.
[Journal]
95)  Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, Greten TF, Hruban RH, Yeo CJ, Griffin CA.
Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials.
Cancer J Sci Am. 4: 194-203, 1998.
[Journal]
96)  Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP.
Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients.
Proc. Natl. Acad. Sci. U.S.A. 95: 7568-73, 1998.
[Journal]
97)  Thomas MC, Greten TF, Pardoll DM, Jaffee EM.
Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine.
Hum. Gene Ther. 9: 835-43, 1998.
[Journal]
98)  Sinha B, Eigler A, Baumann KH, Greten TF, Moeller J, Endres S.
Nitric oxide downregulates tumour necrosis factor in mRNA in RAW 264.7 cells.
Res. Immunol. 149: 139-50, 1998.
[Journal]
99)  Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S.
Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis.
Scand. J. Immunol. 45: 132-9, 1997.
[Journal]
100)  Siegmund B, Eigler A, Moeller J, Greten TF, Hartmann G, Endres S.
Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.
Eur. J. Pharmacol. 321: 231-9, 1997.
[Journal]
101)  Greten TF, Sinha B, Haslberger C, Eigler A, Endres S.
Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
Eur. J. Pharmacol. 299: 229-33, 1996.
[Journal]
102)  Greten TF, Moeller J, Feldmeier H, Eigler A, Endres S.
Synthesis of tumour necrosis factor-alpha in tissue culture of rat caecum: lack of suppression by phosphodiesterase inhibitors and prostanoids.
Eur J Gastroenterol Hepatol. 8: 679-84, 1996.
[Journal]
103)  Angel JB, Saget BM, Walsh SP, Greten TF, Dinarello CA, Skolnik PR, Endres S.
Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
AIDS. 9: 1137-44, 1995.
[Journal]
104)  Greten TF, Eigler A, Sinha B, Moeller J, Endres S.
The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
Int. J. Immunopharmacol. 17: 605-10, 1995.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 6/18/2014.